Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab but Sirukumab did not go forward in RA. Another kid on block - Olokizumab IL6 receptor blocker with +RA RCT #RWCS2020 @RWCSmtg @RheumNow https://t.co/OwhnRjwPrt